Literature DB >> 23778448

Multidisciplinary acute care research organization (MACRO): if you build it, they will come.

Barbara J Early1, David T Huang, Clifton W Callaway, Mazen Zenati, Derek C Angus, Scott R Gunn, Donald M Yealy, Daniel Unikel, Timothy R Billiar, Andrew B Peitzman, Jason L Sperry.   

Abstract

BACKGROUND: Clinical research will increasingly play a core role in the evolution and growth of acute care surgery program development across the country. What constitutes an efficient and effective clinical research infrastructure in the current fiscal and academic environment remains obscure. We sought to characterize the effects of implementation of a multidisciplinary acute care research organization (MACRO) at a busy tertiary referral university setting.
METHODS: In 2008, to minimize redundancy and cost as well as to maximize existing resources promoting acute care research, MACRO was created, unifying clinical research infrastructure among the Departments of Critical Care Medicine, Emergency Medicine, and Surgery. During the periods 2008 to 2012, we performed a retrospective analysis and determined volume of clinical studies, patient enrollment for both observational and interventional trials, and staff growth since MACRO's origination and characterized changes over time.
RESULTS: From 2008 to 2011, the volume of patients enrolled in clinical studies, which MACRO facilitates has significantly increased more than 300%. The percentage of interventional/observational trials has remained stable during the same period (50-60%). Staff has increased from 6 coordinators to 10, with an additional 15 research associates allowing 24/7 service. With this significant growth, MACRO has become financially self-sufficient, and additional outside departments now seek MACRO's services.
CONCLUSION: Appropriate organization of acute care clinical research infrastructure minimizes redundancy and can promote sustainable, efficient growth in the current academic environment. Further studies are required to determine if similar models can be successful at other acute care surgery programs.

Entities:  

Mesh:

Year:  2013        PMID: 23778448      PMCID: PMC3702269          DOI: 10.1097/TA.0b013e318298779b

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  10 in total

1.  Acute care surgery: what's in a name?

Authors:  L D Britt
Journal:  J Trauma Acute Care Surg       Date:  2012-02       Impact factor: 3.313

2.  Management of duodenal and pancreaticobiliary perforations associated with periampullary endoscopic procedures.

Authors:  Kelly Knudson; Christopher D Raeburn; Robert C McIntyre; Raj J Shah; Raj J Shaw; Yang K Chen; William R Brown; Gregory Stiegmann
Journal:  Am J Surg       Date:  2008-12       Impact factor: 2.565

3.  The role and value of surgical critical care, an essential component of Acute Care Surgery, in the Affordable Care Act: a report from the Critical Care Committee and Board of Managers of the American Association for the Surgery of Trauma.

Authors:  Heidi L Frankel; Karyn L Butler; Joseph Cuschieri; Randall S Friese; Toan Huynh; Alicia M Mohr; Miren A Schinco; Lena M Napolitano; L D Britt; Raul Coimbra; Martin A Croce; James W Davis; Gregory J Jurkovich; Ernest E Moore; John A Morris; Andrew B Peitzman; Basil A Pruitt; Grace S Rozycki; Thomas M Scalea; J Wayne Meredith
Journal:  J Trauma Acute Care Surg       Date:  2012-07       Impact factor: 3.313

4.  Evaluating emergency care research networks: what are the right metrics?

Authors:  Jill M Baren; Melissa K Middleton; Amy H Kaji; Robert E O'Connor; Robert E O'Conner; Christopher Lindsell; Tasmeen Singh Weik; Roger J Lewis
Journal:  Acad Emerg Med       Date:  2009-09-03       Impact factor: 3.451

5.  Patient-centered integrated networks of emergency care: consensus-based recommendations and future research priorities.

Authors:  Prasanthi Govindarajan; Gregory Luke Larkin; Karin V Rhodes; Gina Piazza; Terri L Byczkowski; Meredith Edwards; Jill M Baren
Journal:  Acad Emerg Med       Date:  2010-12       Impact factor: 3.451

6.  Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.

Authors:  M Rooney; J Kish; J Jacobs; J Kinzie; A Weaver; J Crissman; M Al-Sarraf
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

7.  Weekend and night outcomes in a statewide trauma system.

Authors:  Brendan G Carr; Patrick M Reilly; C William Schwab; Charles C Branas; Juliet Geiger; Douglas J Wiebe
Journal:  Arch Surg       Date:  2011-03-21

Review 8.  Lymphomas of the head and neck. 1: Nasofacial T-cell lymphoma.

Authors:  A D Ramsay; N Rooney
Journal:  Eur J Cancer B Oral Oncol       Date:  1993-04

9.  Associated risk factors of human papillomavirus cervical infection among human immunodificiency virus-seropositive women at Siriraj Hospital.

Authors:  Korakot Sirimai; Amphan Chalermchockcharoenkit; Anuwat Roongpisuthipong; Suchittra Pongprasobchai
Journal:  J Med Assoc Thai       Date:  2004-03

10.  Structure and function of emergency care research networks: strengths, weaknesses, and challenges.

Authors:  Linda Papa; Nathan Kuppermann; Katherine Lamond; William G Barsan; Carlos A Camargo; Joseph P Ornato; Ian G Stiell; David A Talan
Journal:  Acad Emerg Med       Date:  2009-10       Impact factor: 3.451

  10 in total
  2 in total

1.  The early evolving sex hormone environment is associated with significant outcome and inflammatory response differences after injury.

Authors:  Samuel J Zolin; Yoram Vodovotz; Raquel M Forsythe; Matthew R Rosengart; Rami Namas; Joshua B Brown; Andrew P Peitzman; Timothy R Billiar; Jason L Sperry
Journal:  J Trauma Acute Care Surg       Date:  2015-03       Impact factor: 3.313

2.  Retooling institutional support infrastructure for clinical research.

Authors:  Denise C Snyder; Rebecca N Brouwer; Cory L Ennis; Lindsey L Spangler; Terry L Ainsworth; Susan Budinger; Catherine Mullen; Jeffrey Hawley; Gina Uhlenbrauck; Mark Stacy
Journal:  Contemp Clin Trials       Date:  2016-04-26       Impact factor: 2.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.